[Prostate cancer screening with a new marker based on circulating blood macrophages?].
Herwig
R
R
Urologische Klinik, Medizinische Universität, Währinger Gürtel 18-20, 1090 Wien, Osterreich. ralf.herwig@meduniwien.ac.at
Djavan
B
B
Kramer
G
G
El-Taieb
M A
MA
Kühhas
F
F
Leers
M
M
Marberger
M
M
D015703:Antigens, CD / Q000032:analysis; D014408:Biomarkers, Tumor / Q000097:blood*; D058851:GPI-Linked Proteins; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000032:analysis; D008264:Macrophages / Q000276:immunology*; D008297:Male; D008403:Mass Screening; D008856:Microscopy, Fluorescence; D009367:Neoplasm Staging; D010587:Phagocytosis / Q000276:immunology; D011237:Predictive Value of Tests; D011467:Prostate / Q000276:immunology / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D012372:ROC Curve; D017452:Receptors, IgG / Q000032:analysis
D015703:Antigens, CD; D014408:Biomarkers, Tumor; C428200:FCGR3B protein, human; D058851:GPI-Linked Proteins; D018950:Lipopolysaccharide Receptors; D017452:Receptors, IgG; D017430:Prostate-Specific Antigen